Novel approaches in the management of myeloma-related skeletal complications

Supportive Cancer Therapy

Volumn 4, Issue 1, 2006, Pages 15-18

  Reddy, G Kesava ^a   Mughal, Tariq I ^b   Roodman, G David ^c  

^a CIG Media Group   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Denosumab; Interteukin 3; Macrophage inflammatory protein 1 ; Osteoprotegerin; RANK; RANKL; Wnt signaling pathway

Indexed keywords

AMG 162; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR 1; CHEMOKINE RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; TELOPEPTIDE; UNCLASSIFIED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

ANEMIA; ASTHENIA; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; FATIGUE; HUMAN; JAW; KIDNEY FAILURE; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL EDEMA; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 33751167602     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.026     Document Type: Review

References (24)

1. Huston A, Roodman GD. Role of the microenvironment in multiple myeloma bone disease. Future Oncol 2006; 2:371-378.
2. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001; 38:276-285.
3. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006 [Epub ahead of print].
4. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005; 16:1223-1231.
5. Berenson JR, Rajdev L, Broder M. Bone complications in multiple myeloma. Cancer Biol Ther 2006 [Epub ahead of print].
6. Yeh HS, Berenson JR. Myeloma bone disease and treatment options. Eur J Cancer 2006; 42:1554-1563.
7. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81:1047-1053.
8. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006; 14:408-418. 2006.
9. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704:49-57.
10. Kwan Tat S, Padrines M, Theoleyre S, et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15:49-60.
11. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5:618-625.
12. Peterson MC, Martin SW, Stouch B, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of AMG 162, a fully human monoclonal antibody to receptor activator of NF kappa B ligand (RANKL), following a single subcutaneous dose to patients with cancer-related bone lesions. Proc Am Soc Clin Oncol 2004; 23:751 (Abstract #8106).
13. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-1228.
14. Lipton A. RANK ligand inhibition: therapeutic role in cancer. Presented at: Fifth Annual International Congress on Monoclonal Antibodies in Cancer; August 11-14, 2005; Quebec City, Canada.
15. Suarez T, Fizazi K, Rahim Y, et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. J Clin Oncol 2006; 24(18 suppl):483s (Abstract #8562).
16. Roodman GD. Myeloma bone disease: clinical challenges. Presented at: Third Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia. September 8-10, 2006; Sarasota, FL.
17. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005; 33:272-278.
18. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108:1833-1841.
19. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100:2195-2202.
20. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103:2308-2315.
21. Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106:1407-1414.
22. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341:19-39.
23. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-2494.
24. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106:3160-3165.